Participation in editorial boards of scientific journals/book series: -Editorial Board: BMC Cancer, 2021-
-Editorial Board: Diagnostic Pathology, 2021-
-Editorial Board: Chinese Clinical Oncology, 2020-
-Guest Editor: Cancer Organoids in Basic Science and Translational Medicine, Cancers, 2019
-Guest Editor: Breakthrough in drug discovery and delivery in oncology, Molecules, 2019
-Guest Editor: Biocompatible Materials in Drug Delivery System in Oncology, Pharmaceutics, 2019
-Guest Editor: Recent Advances in Nanomedicine for Cancer Treatment, Journal of Oncology, Hindawi, 2019
-Guest Editor: Peptidyl-prolyl Isomerases in Human Pathologies. Frontiers in Pharmacology, 2018
-Guest Editor: Nanomedicine in cancer. Current Medicinal Chemistry, 2016
-Frontiers in Nanoscience and Nanotechnology, OAT 2016-
-Nanomedicine & Nanoscience Research, Gavin publisher 2016-

Participation as referees of national and international research projects: TRANSCAN projects
National Research Foundation-Republic of South Africa
Swiss National Foundation

Main departmental research areas and fields: Area: Biomedicina Linea: Diagnosi
Area: Biomedicina Linea: Salute e Benessere
Area: Biomedicina Linea: Terapia
Area: Biomedicina

Research skills

Sviluppo di farmaci in ambito oncologico

Description:: Drug discovery for cancer

Keywords:: Health sciences, Anticancer therapy, Nanosystems

ATECO code:: [72] - ricerca scientifica e sviluppo

Nanomateriali per la veicolazione di farmaci

Description:: Nanotechnology for drug delivery

Keywords:: Technological sciences, Nanosystems

ATECO code:: [72] - ricerca scientifica e sviluppo

Completed and pending researches

Functional analysis of cell cycle genes in cancer

SSD:: BIO/11

Genetic and epigenetic analysis of X linked candidate genes for Premature Ovarian Failure

SSD:: BIO/11

Organ-on-chip

SSD:: BIO/11

Targeted therapy in colorectal and ovarian cancers and development of new drug delivery systems

SSD:: BIO/11

Funds

A novel nanopharmaceutical formulation for the treatment of solid tumors

Funding body:: Ministero della Salute

Type:: Altri programmi ministeriali

Role in the project:: LD

Starting date:: Year: 2024 Length in months: 36

Cibo intelligente per un futuro sostenibile

Funding body:: Regione Veneto

Type:: POR FESR (2014-2020)

Role in the project:: PT

Starting date:: Year: 2017 Length in months: 12

Development of a diagnostic kit to isolate circulating exosomes in patients with ovarian cancer

Funding body:: AREA Science Park

Type:: Altri finanziamenti per progetti di ricerca

Role in the project:: PT

Starting date:: Year: 2015 Length in months: 12

ISE-EMH, Ecosistema italo-sloveno per la sanità elettronica e mobile

Funding body:: Europa

Type:: Interreg V Italia - Slovenia

Role in the project:: PT

Sito di progetto:: https://www.ita-slo.eu/it/ise-emh

Starting date:: Year: 2020 Length in months: 36

Inhibition of Pin1 to improve carboplatin and taxol cytotoxicity in high-grade serous ovarian cancer

Funding body:: AIRC

Type:: Altri finanziamenti per progetti di ricerca

Role in the project:: NS

Starting date:: Year: 2015 Length in months: 36

Nanosalus: Nanomateriali terapeutici a delivery ottimizzato per la salute umana

Funding body:: MIMIT

Type:: Altri programmi ministeriali

Role in the project:: LD

Starting date:: Year: 2023 Length in months: 36

New diagnostic and therapeutic tools against multidrug resistant tumors

Funding body:: Europa

Type:: COST

Role in the project:: PT

Sito di progetto:: https://stratagem-cost.eu/

Starting date:: Year: 2018 Length in months: 48

PIN1 targeted therapy in high grade serous ovarian cancer patients

Funding body:: AIRC

Type:: Altri finanziamenti per progetti di ricerca

Role in the project:: LD

Starting date:: Year: 2020 Length in months: 60

PREDIzione Tumori Tiroidei

Funding body:: Regione Friuli Venezia Giulia

Type:: POR FESR (2014-2020)

Role in the project:: PT

Starting date:: Year: 2018 Length in months: 36

Produzione di fattori di crescita in pianta per la produzione di proteine alternative

Funding body:: POR-FSE Veneto

Type:: POR FSE (2014-2020)

Role in the project:: LD

Starting date:: Year: 2023 Length in months: 12

Sensori elettrochimici e kit biomolecolari per l'analisi di contaminanti emergenti in prodotti agroalimentari

Funding body:: FSE

Type:: POR FESR (2014-2020)

Role in the project:: LD

Starting date:: Year: 2017 Length in months: 12

Sviluppo di procedure standardizzate per la valutazione di microplastiche in prodotti agroalimentari

Funding body:: Regione Veneto

Type:: POR FESR (2014-2020)

Role in the project:: LD

Starting date:: Year: 2020 Length in months: 15

TIGER

Funding body:: Europa

Type:: Interreg IV Spazio Alpino

Role in the project:: PT

Starting date:: Year: 2024 Length in months: 36

Tumoroids as new REAl Time therapy for High Grade Serous Epithelial Ovarian Cancer patients

Funding body:: Università Ca' Foscari

Type:: Progetti di Ateneo

Role in the project:: LD

Starting date:: Year: 2019 Length in months: 24

Publication highlights

Botter, Eleonora; Lauteri, Valentina; Rubbi, Alessandro; Orian, Laura; Forner, Matteo; Gandin, Valentina; Demitri, Nicola; Canzonieri, Vincenzo; Rizzolio, Flavio; Cavarzerani, Enrico; Visentin, Fabiano; Scattolin, Thomas Insertion of SnCl2 into the Pd–Cl bond: mechanistic elucidation and antitumor evaluation of trichlorostannyl palladium–NHC allyl complexes in ovarian cancer models in DALTON TRANSACTIONS, vol. 55, pp. 6351-6372 (ISSN 1477-9226)
DOI 2026, Journal Article - ARCA card: 10278/5116932

Saorin, Gloria; Mauceri, Matteo; Caligiuri, Isabella; Kamensek, Urska; Kranjc Brezar, Simona; Corona, Giuseppe; Repetto, Ombretta; Perin, Tiziana; Grassi, Gabriele; Granchi, Carlotta; Tuccinardi, Tiziano; Cemazar, Maja; Canzonieri, Vincenzo; Adeel, Muhammad; Rizzolio, Flavio Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer in CANCER LETTERS, vol. 637, pp. 218128 (ISSN 0304-3835)
DOI 2026, Journal Article - ARCA card: 10278/5112410

Singh, Mamta; Yadav, Anubha; Singh, Umesh; Gupta, Rajat; Cavarzerani, Enrico; Canzonieri, Vincenzo; Negi, Deepraj; Dagar, Akansha; Sathyamoorthy, Bharathwaj; Rizzolio, Flavio; Kumar, Sushil; Baliyan, Ankur; Rani, Reshma; Kumar, Vinit Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth in CHEMMEDCHEM, vol. 21 (ISSN 1860-7179)
DOI 2026, Journal Article - ARCA card: 10278/5112408

Tonon, Giovanni; Rafaniello, Anna; Mauceri, Matteo; Demitri, Nicola; Scattolin, Thomas; Rizzolio, Flavio; Visentin, Fabiano Palladium(0) and Juglone: a new alliance in the fight against ovarian cancer in DALTON TRANSACTIONS, vol. 55, pp. 445-459 (ISSN 1477-9226)
DOI 2026, Journal Article - ARCA card: 10278/5112409

Arnaut, Pierre; Pozsoni, Nestor Bracho; Bondar, Denys; Lippmann, Petra; Boschuk, Susanne; Semenyuta, Ivan; Bhandary, Subhrajyoti; Van Hecke, Kristof; Karpichev, Yevgen; Cavarzerani, Enrico; Canzonieri, Vincenzo; Rizzolio, Flavio; Scattolin, Thomas; Vougioukalakis, Georgios C.; Ott, Ingo; Tzouras, Nikolaos V.; Nolan, Steven P. A new generation of N-heterocyclic carbene (NHC) gold–selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models in CHEMICAL SCIENCE, vol. 16, pp. 17221-17231 (ISSN 2041-6520)
DOI 2025, Journal Article - ARCA card: 10278/5112407

List of publications

List of selected publications

Curriculum vitae

Dr. Rizzolio is full professor in molecular biology at the Department of Molecular Sciences and Nanosystems at Ca' Foscari University. He obtained the specialization in Applied Genetics in 2004 at University of Pavia. During the period 2007- 2011, he worked at the Department of Biology of Temple University (Philadelphia, USA) as a Visiting Research Scholar. During this time, he completed the PhD program in oncology and genetics. On 1 February 2011, he received the title of Assistant Professor at Temple University.

The research activity of Dr. Rizzolio can be summarized in three periods. First phase (2000-2007): his scientific career began in 2000 with the thesis focused on the molecular and genetic analysis of two genes mapped on chromosome X candidate Premature ovarian failure (POF). It was also studied the effects of the interaction of the X and autosome chromosomes on the expression of flanking genes in POF patients with X-autosome balanced translocation. During this scientific period, he improved many basic techniques of molecular biology and genetics. Second stage (2007-2011): during the PhD program, he studied the role of may proteins involved in cell cycle control of cancer cells. In particular, it has been investigated the role of Retinoblastoma family of proteins and Pin1. During this scientific step, he improved many basic techniques of molecular/cellular biology and animal models. Third phase (2011-2016): Development of biocompatible nanodrugs in oncology. At the Centro di Riferimento Oncologico and now at Ca' Foscari University, he is working on the development of new nanodrugs based on biocompatible materials (DNA, Liposomes, exosomes). He published more than 200 research papers and he is a member of the Editorial Advisory Board of the following journals: Nanomedicine & Nanoscience Research and Frontiers in Nanoscience. He is the founder and CEO of BioFuture Medicine.

Last update: 27/02/2026
The information above has been uploaded on Ca' Foscari website directly by the person this webpage refers to. The correctness and the truthfulness of the published information are the responsibility of the relevant person.

cafoscariNEWS

17/02/2025

Type	Name	Sender (Domain)	Description	Duration	Policy
Essential	_shibsession[], _shibsstate[]	Unive.it (www.unive.it)	They maintain the session data of the SingleSignOn.	session	Information
Essential	PHPSESSID	Unive.it (www.unive.it)	Unique user identifier for the website applications.	session	Information
Essential	cookie[*]	Unive.it (www.unive.it)	It stores the user's preferences on cookies. user preferences on cookies.	1 month	Information
Essential	cookie	idp.unive.it	It stores the user's preferences on cookies.	1 month	Information
Essential	fe_typo_user	Unive.it (www.unive.it)	Unique user identifier for the reserved area of the website	session	Information
Essential	JSESSIONID	Unive.it (www.unive.it)	Used to create web sessions into the Personal Area.	session	Information
Essential	ADMCMD_prev	Unive.it (www.unive.it)	Used to create web sessions into the Personal Area.	session	Information
Essential	unive.it	Unive.it (www.unive.it)	It stores the user's preferences on cookies.	6 months	Information
Essential	noiframe	Unive.it (www.unive.it)	It stores the user's preferences on cookies.	6 months	Information
Essential	_pk_id[*]	unive/WAI	*	30 days	Information
Essential	_pk_ses[*]	unive/WAI	*	1 day	Information
Essential	_pk_ref[*]	unive/WAI	*	6 months	Information
Essential	_gsas[*]	unive/google	It stores the user's preferences on cookies.	3 months	Information
Essential	_opensaml_req_cookie%[*]	unive	Authentication and SingleSignOn (shibboleth)	session	Information
Google - Youtube	__Secure-1PAPISID	Google (google.com)	Used for targeting purposes in order to acquire web visitors' interests and show them pertinent and customised Google advertising.	2 years	Information
Google - Youtube	CONSENT	Google (google.com)	Used by Google to store the user's preferences.	17 years	Information
Google - Youtube	__Secure-1PSID	Google (google.com)	Used for targeting purposes in order to acquire web visitors' interests and show them pertinent and customised Google advertising.	2 years	Information

Flavio RIZZOLIO

Office hours

Teaching activity current year

Teaching activity previous years

Activities and research skills

Publication highlights

List of publications

Curriculum vitae

cafoscariNEWS

Il palladio contro i tumori ovarici: brevetti cafoscarini verso il mercato

'Domino' di radicali liberi contro le cellule tumorali

'Insieme': a multilingual Italian-Slovenian online healthcare platform

Nasce 'Insieme', la piattaforma di servizi per pazienti oncologici

Ca' Foscari con AIRC per due progetti di ricerca sul cancro

Da spinoff cafoscarino un kit per potenziare la ricerca sul cancro

Cookie Policy - Privacy notice provided in accordance with EU Regulation 2016/679

1. Data Controller

2. Data Protection Officer

3. Types of cookies, data collect, purposes and legal basis

4. Means of data processing

5. Data retention

6. Recipients and categories of recipients of personal data and data transfer outside the European Economic Area

7. Data subjects rights and how to exercise them

Appendix on social media: